[go: up one dir, main page]

MX2021001672A - Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. - Google Patents

Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.

Info

Publication number
MX2021001672A
MX2021001672A MX2021001672A MX2021001672A MX2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A MX 2021001672 A MX2021001672 A MX 2021001672A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequence
sequence number
sequence represented
hla
Prior art date
Application number
MX2021001672A
Other languages
English (en)
Inventor
Young Ho Kim
Byoung Se Kwon
Kwang Hee Kim
Ji Won Chung
Young Gyoon Chang
Bo Rim Yi
Jung Yun Lee
Seung Hyun Lee
Sun Woo Im
Jin Kyung Choi
Hyun Tae Son
Eun Hye Yoo
Original Assignee
Eutilex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd
Publication of MX2021001672A publication Critical patent/MX2021001672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una molécula de unión a antígeno que comprende una región variable de cadena pesada que comprende una región determinante de la complementariedad 1 de cadena pesada (HCDR1) que comprende una secuencia de aminoácidos representada por la Secuencia N.º 1, una HCDR2 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 2 y una HCDR3 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 3; una región variable de cadena ligera que comprende una región determinante de la complementariedad 1 de cadena ligera (LCDR1) que comprende una secuencia de aminoácidos representada por la Secuencia N.º 4, una LCDR2 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 5 y una LCDR3 que comprende una secuencia de aminoácidos representada por la Secuencia N.º 6; en donde la molécula de unión a antígeno es un receptor de linfocitos T (TCR); y a una línea de células que expresa el mismo.
MX2021001672A 2018-08-10 2019-08-12 Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. MX2021001672A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717267P 2018-08-10 2018-08-10
US201962867503P 2019-06-27 2019-06-27
PCT/KR2019/010244 WO2020032784A1 (ko) 2018-08-10 2019-08-12 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포

Publications (1)

Publication Number Publication Date
MX2021001672A true MX2021001672A (es) 2021-07-15

Family

ID=69414238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001672A MX2021001672A (es) 2018-08-10 2019-08-12 Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.

Country Status (11)

Country Link
US (2) US11013765B2 (es)
EP (1) EP3835320A4 (es)
JP (1) JP7539161B2 (es)
KR (1) KR102842215B1 (es)
CN (1) CN113366017B (es)
AU (1) AU2019317229A1 (es)
BR (1) BR112021002487A2 (es)
CA (1) CA3109209A1 (es)
MX (1) MX2021001672A (es)
SG (1) SG11202101169PA (es)
WO (1) WO2020032784A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
CN113366017B (zh) * 2018-08-10 2024-05-28 优特力克斯有限公司 结合hla-dr的嵌合抗原受体和car-t细胞
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
KR102671408B1 (ko) * 2021-02-26 2024-06-04 진화섭 HLA class II에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
KR20220144327A (ko) * 2021-04-15 2022-10-26 주식회사 유틸렉스 Hla-dr 특이적 키메라 항원 수용체 및 이의 용도
EP4362958A4 (en) * 2021-06-30 2025-08-20 New York Genome Center Inc METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOTHERAPY
US20250230246A1 (en) * 2021-10-27 2025-07-17 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
WO2025193710A2 (en) * 2024-03-11 2025-09-18 New York University Methods and compositions for use of tumor specific antigens in adoptive immunotherapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023325A (en) 1911-10-21 1912-04-16 Frank B Miller Poultry-feeder.
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1988001630A1 (fr) 1986-09-04 1988-03-10 Nikkiso Co., Ltd. Materiau composite renforce par barbes
ATE113985T1 (de) 1987-03-20 1994-11-15 Creative Biomolecules Inc Verfahren zur reinigung von rekombinanten polypeptiden.
EP0305481B1 (en) 1987-03-20 1993-09-29 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
KR100701923B1 (ko) 2006-03-15 2007-03-30 주식회사 녹십자 항- ｂ림프종 단일클론항체 및 이를 생산하는 하이브리도마세포주
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
GB2481983A (en) 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3421489B1 (en) * 2012-03-23 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
CA2878928C (en) * 2012-07-13 2023-03-14 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars
KR102685501B1 (ko) 2013-02-20 2024-07-17 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
KR101605421B1 (ko) * 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
EP3230321B1 (en) 2014-12-12 2019-08-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016197064A1 (en) 2015-06-04 2016-12-08 Epstein Alan L Lym-1 and lym-2 targeted car cell immunotherapy
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CN116041538A (zh) 2015-12-03 2023-05-02 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018057904A1 (en) 2016-09-23 2018-03-29 University Of Southern California Chimeric antigen receptors and compositions and methods of use thereof
CN110753754A (zh) 2017-02-21 2020-02-04 优特力克斯有限公司 Hla-dr car-t组合物以及制备方法和使用方法
CN113366017B (zh) * 2018-08-10 2024-05-28 优特力克斯有限公司 结合hla-dr的嵌合抗原受体和car-t细胞
MX2021015967A (es) * 2019-06-27 2022-04-06 Eutilex Co Ltd Receptor de antigeno quimerico con dominio coestimulador 4-1bb.

Also Published As

Publication number Publication date
US11013765B2 (en) 2021-05-25
SG11202101169PA (en) 2021-03-30
AU2019317229A1 (en) 2021-02-18
EP3835320A1 (en) 2021-06-16
BR112021002487A2 (pt) 2021-07-27
CN113366017A (zh) 2021-09-07
US20220031742A1 (en) 2022-02-03
US11951130B2 (en) 2024-04-09
US20200237821A1 (en) 2020-07-30
JP2021533755A (ja) 2021-12-09
CA3109209A1 (en) 2020-02-13
KR102842215B1 (ko) 2025-08-05
EP3835320A4 (en) 2022-06-01
WO2020032784A1 (ko) 2020-02-13
CN113366017B (zh) 2024-05-28
KR20210043623A (ko) 2021-04-21
JP7539161B2 (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
MX2021001672A (es) Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
IL277242B2 (en) Antibodies that bind cd39 and uses thereof
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CO6230999A2 (es) Anticuerpo anti-esclerostina
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20140196A1 (es) Anticuerpos anti-cd37
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
NZ740221A (en) St2l antagonists and methods of use
FI3596125T3 (fi) Anti-PAR2-vasta-aineita ja niiden käyttöjä
RU2010133547A (ru) Анти-cldn антитела